BioInvent is a research-based pharmaceutical company that focuses on developing antibody drugs against cancer. The Company's pipeline currently includes three product candidates for the treatment of cancer:
The antibody library n-CoDeR and screening tool FIRST are two patented tools that enable the identification of relevant human antibodies and disease targets during the discovery phase. This platform is also utilized by partners who finance the development of new drugs which makes BioInvent entitled to milestone payments and royalties on sales. Such partners include Bayer HealthCare, Daiichi Sankyo, Mitsubishi Tanabe, Servier and XOMA.
BioInvent is traded on Stockholm Stock Exchange.
Market Cap (2016-01-01) SEK 617.46M ($73,15M) Recent headlines
BioInvent Selected for Manufacturing Services by Global Pharmaceutical Company; Expects to Generate about SEK 25 Million in Revenue http://finance.yahoo.com/news/bioinvent-selected-manufacturing-services-global-074600912.html
BioInvent Update on Clinical and Preclinical Drug Programs http://finance.yahoo.com/news/bioinvent-clinical-preclinical-drug-programs-075000373.html
BioInvent in-Licenses Cutting Edge Technology to Pave the Way for More Efficacious Cancer Treatments http://finance.yahoo.com/news/bioinvent-licenses-cutting-edge-technology-082600652.html
Q3 2015 BioInvent International AB Earnings Release http://biz.yahoo.com/research/earncal/20151022.html?t=binv.st
BioInvent Interim Report 1 January – 30 September 2015 http://finance.yahoo.com/news/bioinvent-interim-report-1-january-064600196.html